Go Pro

Humana (HUM) Competitors

Humana logo
$379.22 -1.51 (-0.40%)
As of 08/21/2026 03:58 PM Eastern

HUM vs. CI, CNC, ELV, MOH, and UNH

Should you buy Humana stock or one of its competitors? Humana's main competitors and comparable companies include Cigna Group (CI), Centene (CNC), Elevance Health (ELV), Molina Healthcare (MOH), and UnitedHealth Group (UNH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare providers & services" industry.

How does Humana compare to Cigna Group?

Humana (NYSE:HUM) and Cigna Group (NYSE:CI) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Humana pays an annual dividend of $3.54 per share and has a dividend yield of 0.9%. Cigna Group pays an annual dividend of $6.24 per share and has a dividend yield of 2.3%. Humana pays out 33.5% of its earnings in the form of a dividend. Cigna Group pays out 25.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cigna Group has increased its dividend for 5 consecutive years. Cigna Group is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Cigna Group had 18 more articles in the media than Humana. MarketBeat recorded 38 mentions for Cigna Group and 20 mentions for Humana. Cigna Group's average media sentiment score of 1.47 beat Humana's score of 1.05 indicating that Cigna Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Humana
13 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cigna Group
33 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Humana has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Cigna Group has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Cigna Group has higher revenue and earnings than Humana. Cigna Group is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Humana$129.66B0.35$1.19B$10.5735.88
Cigna Group$274.90B0.27$5.96B$24.1711.43

Cigna Group has a net margin of 2.27% compared to Humana's net margin of 0.88%. Cigna Group's return on equity of 19.75% beat Humana's return on equity.

Company Net Margins Return on Equity Return on Assets
Humana0.88% 11.20% 3.94%
Cigna Group 2.27%19.75%5.34%

Humana presently has a consensus target price of $395.22, suggesting a potential upside of 4.22%. Cigna Group has a consensus target price of $339.45, suggesting a potential upside of 22.90%. Given Cigna Group's stronger consensus rating and higher probable upside, analysts clearly believe Cigna Group is more favorable than Humana.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humana
1 Sell rating(s)
15 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.43
Cigna Group
0 Sell rating(s)
7 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.68

92.4% of Humana shares are owned by institutional investors. Comparatively, 87.0% of Cigna Group shares are owned by institutional investors. 0.2% of Humana shares are owned by insiders. Comparatively, 0.6% of Cigna Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cigna Group beats Humana on 15 of the 19 factors compared between the two stocks.

How does Humana compare to Centene?

Humana (NYSE:HUM) and Centene (NYSE:CNC) are both large-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Humana has higher earnings, but lower revenue than Centene. Centene is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Humana$129.66B0.35$1.19B$10.5735.88
Centene$194.78B0.16-$6.67B-$10.44N/A

Humana has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Centene has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Humana has a net margin of 0.88% compared to Centene's net margin of -2.51%. Centene's return on equity of 12.12% beat Humana's return on equity.

Company Net Margins Return on Equity Return on Assets
Humana0.88% 11.20% 3.94%
Centene -2.51%12.12%3.20%

92.4% of Humana shares are owned by institutional investors. Comparatively, 93.6% of Centene shares are owned by institutional investors. 0.2% of Humana shares are owned by company insiders. Comparatively, 0.4% of Centene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Centene had 16 more articles in the media than Humana. MarketBeat recorded 36 mentions for Centene and 20 mentions for Humana. Centene's average media sentiment score of 1.12 beat Humana's score of 1.05 indicating that Centene is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Humana
13 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Centene
25 Very Positive mention(s)
1 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Humana presently has a consensus price target of $395.22, suggesting a potential upside of 4.22%. Centene has a consensus price target of $70.05, suggesting a potential upside of 7.87%. Given Centene's higher possible upside, analysts clearly believe Centene is more favorable than Humana.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humana
1 Sell rating(s)
15 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.43
Centene
2 Sell rating(s)
9 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.40

Summary

Centene beats Humana on 9 of the 17 factors compared between the two stocks.

How does Humana compare to Elevance Health?

Humana (NYSE:HUM) and Elevance Health (NYSE:ELV) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Humana has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Elevance Health has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Humana pays an annual dividend of $3.54 per share and has a dividend yield of 0.9%. Elevance Health pays an annual dividend of $6.88 per share and has a dividend yield of 1.7%. Humana pays out 33.5% of its earnings in the form of a dividend. Elevance Health pays out 30.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Elevance Health has increased its dividend for 14 consecutive years. Elevance Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Elevance Health has a net margin of 2.47% compared to Humana's net margin of 0.88%. Elevance Health's return on equity of 14.64% beat Humana's return on equity.

Company Net Margins Return on Equity Return on Assets
Humana0.88% 11.20% 3.94%
Elevance Health 2.47%14.64%5.22%

Humana presently has a consensus price target of $395.22, suggesting a potential upside of 4.22%. Elevance Health has a consensus price target of $440.90, suggesting a potential upside of 10.04%. Given Elevance Health's stronger consensus rating and higher possible upside, analysts plainly believe Elevance Health is more favorable than Humana.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humana
1 Sell rating(s)
15 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.43
Elevance Health
0 Sell rating(s)
8 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)
2.65

Elevance Health has higher revenue and earnings than Humana. Elevance Health is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Humana$129.66B0.35$1.19B$10.5735.88
Elevance Health$199.13B0.44$5.66B$22.5017.81

In the previous week, Elevance Health had 21 more articles in the media than Humana. MarketBeat recorded 41 mentions for Elevance Health and 20 mentions for Humana. Elevance Health's average media sentiment score of 1.70 beat Humana's score of 1.05 indicating that Elevance Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Humana
13 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Elevance Health
40 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

92.4% of Humana shares are held by institutional investors. Comparatively, 89.2% of Elevance Health shares are held by institutional investors. 0.2% of Humana shares are held by insiders. Comparatively, 0.3% of Elevance Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Elevance Health beats Humana on 16 of the 19 factors compared between the two stocks.

How does Humana compare to Molina Healthcare?

Humana (NYSE:HUM) and Molina Healthcare (NYSE:MOH) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Humana has higher revenue and earnings than Molina Healthcare. Molina Healthcare is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Humana$129.66B0.35$1.19B$10.5735.88
Molina Healthcare$45.43B0.23$472M-$0.18N/A

Humana has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Molina Healthcare has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

Humana currently has a consensus price target of $395.22, suggesting a potential upside of 4.22%. Molina Healthcare has a consensus price target of $202.44, suggesting a potential upside of 0.90%. Given Humana's stronger consensus rating and higher probable upside, equities research analysts plainly believe Humana is more favorable than Molina Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humana
1 Sell rating(s)
15 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.43
Molina Healthcare
2 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.18

Humana has a net margin of 0.88% compared to Molina Healthcare's net margin of -0.02%. Humana's return on equity of 11.20% beat Molina Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Humana0.88% 11.20% 3.94%
Molina Healthcare -0.02%3.73%0.97%

92.4% of Humana shares are held by institutional investors. Comparatively, 98.5% of Molina Healthcare shares are held by institutional investors. 0.2% of Humana shares are held by company insiders. Comparatively, 1.4% of Molina Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Humana had 6 more articles in the media than Molina Healthcare. MarketBeat recorded 20 mentions for Humana and 14 mentions for Molina Healthcare. Humana's average media sentiment score of 1.05 beat Molina Healthcare's score of 0.89 indicating that Humana is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Humana
13 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Molina Healthcare
9 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Humana beats Molina Healthcare on 13 of the 17 factors compared between the two stocks.

How does Humana compare to UnitedHealth Group?

Humana (NYSE:HUM) and UnitedHealth Group (NYSE:UNH) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Humana presently has a consensus price target of $395.22, suggesting a potential upside of 4.22%. UnitedHealth Group has a consensus price target of $455.92, suggesting a potential upside of 16.62%. Given UnitedHealth Group's stronger consensus rating and higher probable upside, analysts clearly believe UnitedHealth Group is more favorable than Humana.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Humana
1 Sell rating(s)
15 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.43
UnitedHealth Group
0 Sell rating(s)
5 Hold rating(s)
20 Buy rating(s)
2 Strong Buy rating(s)
2.89

Humana has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, UnitedHealth Group has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

UnitedHealth Group has higher revenue and earnings than Humana. UnitedHealth Group is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Humana$129.66B0.35$1.19B$10.5735.88
UnitedHealth Group$447.57B0.78$12.06B$15.5425.16

UnitedHealth Group has a net margin of 3.14% compared to Humana's net margin of 0.88%. UnitedHealth Group's return on equity of 16.53% beat Humana's return on equity.

Company Net Margins Return on Equity Return on Assets
Humana0.88% 11.20% 3.94%
UnitedHealth Group 3.14%16.53%5.43%

Humana pays an annual dividend of $3.54 per share and has a dividend yield of 0.9%. UnitedHealth Group pays an annual dividend of $9.28 per share and has a dividend yield of 2.4%. Humana pays out 33.5% of its earnings in the form of a dividend. UnitedHealth Group pays out 59.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. UnitedHealth Group has raised its dividend for 15 consecutive years. UnitedHealth Group is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

92.4% of Humana shares are held by institutional investors. Comparatively, 87.9% of UnitedHealth Group shares are held by institutional investors. 0.2% of Humana shares are held by company insiders. Comparatively, 0.2% of UnitedHealth Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, UnitedHealth Group had 65 more articles in the media than Humana. MarketBeat recorded 85 mentions for UnitedHealth Group and 20 mentions for Humana. UnitedHealth Group's average media sentiment score of 1.26 beat Humana's score of 1.05 indicating that UnitedHealth Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Humana
13 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
UnitedHealth Group
65 Very Positive mention(s)
8 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
3 Very Negative mention(s)
Positive

Summary

UnitedHealth Group beats Humana on 15 of the 20 factors compared between the two stocks.

Get Humana News Delivered to You Automatically

Sign up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HUM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HUM vs. The Competition

MetricHumanaHealthcare Providers & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$45.50B$9.83B$7.38B$24.31B
Dividend Yield0.93%2.55%2.53%3.70%
P/E Ratio35.8834.38272.3330.23
Price / Sales0.355.00623.2621.00
Price / Cash15.75125.1278.6232.49
Price / Book2.364.0513.056.77
Net Income$1.19B$311.06M$3.47B$1.07B
7 Day Performance-2.30%0.83%2.10%-0.65%
1 Month Performance-4.70%1.29%6.12%2.45%
1 Year Performance26.40%15.68%25.00%14.87%

Humana Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HUM
Humana
4.3595 of 5 stars
$379.22
-0.4%
$395.22
+4.2%
+26.4%$45.50B$129.66B35.8867,060
CI
Cigna Group
4.9878 of 5 stars
$278.13
-1.5%
$339.45
+22.0%
-9.2%$73.49B$274.90B11.5167,700
CNC
Centene
3.8209 of 5 stars
$66.51
+1.1%
$68.58
+3.1%
+121.4%$32.86B$202.94BN/A61,100
ELV
Elevance Health
4.8998 of 5 stars
$397.01
+0.7%
$440.90
+11.1%
+26.9%$86.10B$199.13B17.6497,100
MOH
Molina Healthcare
2.7927 of 5 stars
$198.90
+1.2%
$202.44
+1.8%
+15.1%$10.38B$44.52BN/A19,000

Related Companies and Tools


This page (NYSE:HUM) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners